Saturday 17 October 2026
Export CVM’s income statement to Excel — free account
Cel-Sci Corporation
In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
1.79
0.05
+2.87%
Follow CVM
Cel-Sci Corporation (CVM) P/E ratio
Cel-Sci Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2020 | 0.0× | — |
| Jun 2020 | 0.0× | — |
| Mar 2020 | 0.0× | — |
| Dec 2019 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVM Cel-Sci Corporation | n/m |
| RNAZ TransCode Therapeutics Inc. compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| NXTC NextCure, Inc. compare | n/m |
| MGX Metagenomi Therapeutics, Inc. compare | n/m |
| BCTX BRIACELL THERAP compare | 1.5× |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.1× |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)